AstraZeneca reports detailed results from SERENA-2 Phase 3 trial

Detailed results from the SERENA-2 Phase II trial showed AstraZeneca’s next-generation oral selective estrogen receptor degrader camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, at both 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy, the company announced. In the overall population, camizestrant significantly reduced the risk of disease progression or death by 42% at a 75mg dose and 33% at a 150mg dose compared to Faslodex, the current SERD standard of care. Among the prespecified subgroup of patients with ESR1 mutations – comprising 36.7% of the trial population – camizestrant showed a 67% reduction in the risk of disease progression or death at a 75mg dose and a 45% reduction at a 150mg dose compared to Faslodex. Efficacy was also seen in patients without a detectable ESR1 mutation, with a 22% and 24% reduction in the risk of disease progression or death respectively for the 75mg and 150mg dose levels. Results will be presented today in an oral presentation at the 2022 San Antonio Breast Cancer Symposium, or SABCS.